Determining whether an ependymoma is "cancer" involves a nuanced understanding of neuro-oncology and the specific grading system used by the World Health Organization (WHO). Unlike many other types of tumors, the distinction between "benign" and "malignant" in the central nervous system (CNS) is complex. An ependymoma is fundamentally a primary CNS tumor, meaning it originates in the brain or spinal cord, specifically from ependymal cells or their precursors. Whether it is medically classified as cancer depends primarily on its histopathological grade and, increasingly, its molecular characteristics.

In short, Grade 1 ependymomas are generally considered non-cancerous (benign), while Grade 3 ependymomas are considered cancerous (malignant). Grade 2 tumors occupy a middle ground—they are often called "low-grade" but possess the potential for aggressive behavior and recurrence.

Defining Ependymoma and Its Origins

To understand the malignancy of this tumor, one must first understand where it begins. Ependymomas arise from cells that line the ventricles (the fluid-filled spaces of the brain) and the central canal of the spinal cord. These cells, known as ependymal cells, are a type of glial cell responsible for supporting the nervous system and assisting in the circulation of cerebrospinal fluid (CSF).

Research suggests that these tumors may actually originate from radial glial cells, which are precursor cells in the developing brain. Because these cells are intrinsic to the structure of the brain and spine, the tumors they form are integrated into some of the most sensitive areas of the human body.

The WHO Grading System for Ependymoma

The medical community uses the WHO classification system to categorize ependymomas into three distinct grades. This grading is performed by a neuropathologist who examines the tumor tissue under a microscope.

Grade 1 Ependymomas: Non-Cancerous Variants

Grade 1 ependymomas are low-grade, slow-growing tumors. In most medical contexts, these are not classified as "cancer" in the traditional sense because they do not typically invade surrounding healthy tissue or spread aggressively.

  • Subependymoma: This is the most common Grade 1 subtype. They are often found incidentally during imaging for other conditions and are more prevalent in older adults. Subependymomas typically grow very slowly and are well-defined.
  • Clinical Implications: While technically benign, a Grade 1 tumor can still be life-threatening if it blocks the flow of CSF, leading to hydrocephalus (fluid buildup in the brain), which increases intracranial pressure.

Grade 2 Ependymomas: The Low-Grade Challenge

Grade 2 tumors are also described as "low-grade," but they are more complex than Grade 1. They exhibit higher cellularity and a greater likelihood of recurring after treatment.

  • Conventional Ependymoma: This subtype can occur in both children and adults. While they grow more slowly than malignant versions, their boundaries with healthy brain tissue can be less clear, making complete surgical removal difficult.
  • Recurrence Risk: A significant concern with Grade 2 ependymomas is their tendency to return, sometimes as a higher-grade tumor, if any microscopic cells are left behind during surgery.

Grade 3 Ependymomas: Malignant Cancer

Grade 3 ependymomas, often referred to as anaplastic ependymomas, are unequivocally classified as cancer. These tumors are malignant, aggressive, and fast-growing.

  • Characteristics: Under a microscope, Grade 3 cells look highly abnormal, showing rapid division (high mitotic rate) and often forming new blood vessels to fuel their growth (angiogenesis).
  • Invasiveness: These tumors are much more likely to invade nearby brain or spinal cord tissue and can spread through the CSF to other parts of the central nervous system, a process known as drop metastasis.

The 2021 WHO Classification and the Shift to Molecular Subtypes

The traditional "cancer or not" debate has been significantly altered by the 2021 WHO Classification of Tumors of the Central Nervous System (CNS5). Pathologists now recognize that the microscopic appearance (histology) of a tumor does not always predict its behavior. Instead, molecular and genetic markers are now the gold standard for diagnosis.

Supratentorial Ependymomas

Tumors occurring in the upper part of the brain (supratentorial) are now categorized by their genetic fusions:

  • ZFTA Fusion-Positive: Previously known as RELA-fusion, these are typically aggressive and often associated with a Grade 3 behavior, regardless of how they look under a microscope.
  • YAP1 Fusion-Positive: These tend to occur in younger children and generally have a better prognosis than ZFTA-fused tumors, often behaving more like a low-grade tumor.

Posterior Fossa Ependymomas

In the lower back part of the brain (posterior fossa), tumors are divided into:

  • Group A (PFA): Primarily found in infants and young children. These are characterized by a loss of H3 K27me3 protein expression and are known for being difficult to treat and highly prone to recurrence.
  • Group B (PFB): More common in adolescents and adults, these generally have a much more favorable prognosis and are often considered less "cancerous" in their clinical course despite being the same histological grade as PFA.

Spinal Ependymomas

Spinal tumors are also now categorized by molecular traits, such as MYCN amplification. A spinal ependymoma with MYCN amplification is highly aggressive and carries a poor prognosis, distinct from the more common, slower-growing spinal variants seen in adults.

Why Even "Non-Cancerous" Ependymomas Are Serious

In oncology, the term "benign" can be misleading when applied to the brain and spine. The CNS is encased in bone (the skull and spinal column), meaning there is no room for expansion.

  1. Mass Effect: Any tumor, regardless of grade, can press against vital structures. A Grade 1 subependymoma in the fourth ventricle can compress the brainstem, which controls breathing and heart rate.
  2. Obstruction: If a tumor blocks the ventricles, CSF cannot circulate. This leads to a rapid increase in pressure that can be fatal if not addressed with a shunt or surgical resection.
  3. Surgical Complexity: Even if a tumor is not "cancer," its location near critical nerves or blood vessels may make it "inoperable" or high-risk, leading to permanent neurological deficits.

Common Symptoms and Diagnostic Pathways

The symptoms of ependymoma rarely indicate the grade immediately; instead, they reflect the tumor's location.

Intracranial Symptoms (Brain)

  • Headaches: Often worse in the morning due to pressure changes.
  • Nausea and Vomiting: Frequently persistent and unrelated to diet.
  • Ataxia: Difficulty with balance and coordination, common in posterior fossa tumors.
  • Seizures: More common in supratentorial tumors.

Spinal Symptoms

  • Localized Back Pain: Often the first sign.
  • Radiculopathy: Numbness, tingling, or weakness in the limbs.
  • Autonomic Dysfunction: Changes in bowel or bladder control.

The Diagnostic Process

Diagnosis begins with high-resolution MRI with contrast. Ependymomas typically appear as well-defined masses that "light up" or enhance when contrast is administered. However, definitive diagnosis requires a biopsy or surgical resection to analyze the tissue’s cellular and molecular makeup.

Treatment Strategies for Benign and Malignant Ependymomas

The primary goal of treatment is the same for both "cancerous" and "non-cancerous" variants: Maximal Safe Resection.

Surgery

The extent of resection is the single most important factor in determining the outcome. If a surgeon can achieve a "Gross Total Resection" (GTR)—meaning no visible tumor remains on post-operative imaging—the chances of long-term survival increase dramatically. This applies to all grades.

Radiation Therapy

For Grade 3 (malignant) tumors and many Grade 2 tumors, radiation is often used after surgery to kill any remaining microscopic cells. In PFA (Group A) tumors in children, radiation is a standard component of the initial treatment plan due to the high risk of recurrence.

Chemotherapy

The role of chemotherapy in ependymoma is less established than in other cancers. It is typically reserved for very young infants (to delay radiation) or for cases where the tumor has returned after surgery and radiation have failed.

Survival Rates and Long-Term Outlook

The prognosis for ependymoma has improved significantly with modern surgical techniques and molecular targeting. According to the National Cancer Institute (NCI), the overall 5-year relative survival rate for ependymoma is approximately 88.2%.

However, this number is a broad average.

  • Adults with Spinal Ependymomas: Often have excellent outcomes, with survival rates exceeding 90% if the tumor is low-grade and fully resected.
  • Infants with PFA Ependymomas: Face a much more challenging path, with higher rates of recurrence and long-term side effects from treatment.

Conclusion

Is an ependymoma cancer? The answer is "sometimes." While Grade 3 anaplastic ependymomas are malignant cancers, and Grade 1 subependymomas are benign, the reality of the disease lies in its molecular identity and its location within the central nervous system. Even a "non-cancerous" grade can behave aggressively if its molecular subtype is high-risk. For patients and caregivers, the focus has shifted from asking "is it cancer?" to asking "what is the molecular subtype and can it be fully removed?" Advanced genomic testing now provides the most accurate roadmap for treatment and survival.

Frequently Asked Questions

Can a Grade 2 ependymoma become Grade 3?

While less common than in some other brain tumors (like gliomas), an ependymoma can recur as a higher-grade tumor. This is one reason why long-term monitoring with regular MRIs is essential for all patients.

Are ependymomas hereditary?

Most ependymomas are sporadic, meaning they happen by chance. However, there is a known link between spinal ependymomas and Neurofibromatosis Type 2 (NF2). Individuals with NF2 have a genetic predisposition to developing these tumors.

Why is surgery the first choice even for benign grades?

In the brain and spine, a "benign" tumor that continues to grow will eventually cause permanent nerve damage or death by compression. Surgery is the only way to immediately relieve pressure and provide a tissue sample for molecular grading.

Do ependymomas spread to other organs?

Ependymomas rarely spread outside the central nervous system. They do not typically metastasize to the lungs, liver, or bones. Their "metastasis" usually occurs via the cerebrospinal fluid, moving from the brain to the spine or vice versa.

What is the difference between a subependymoma and an ependymoma?

Subependymomas are a specific, Grade 1 variant of ependymal tumors. They are usually slower-growing and less likely to invade nearby tissue than a "conventional" Grade 2 or 3 ependymoma. They are most common in the ventricles of older adults.